PHASEBIO PHARMA - Stock Price History | PHAS

Historical daily share price chart and data for PHASEBIO PHARMA since 2021 adjusted for splits. The latest closing stock price for PHASEBIO PHARMA as of September 24, 2021 is 3.03.
  • The all-time high PHASEBIO PHARMA stock closing price was 14.66 on April 12, 2019.
  • The PHASEBIO PHARMA 52-week high stock price is 5.83, which is 92.4% above the current share price.
  • The PHASEBIO PHARMA 52-week low stock price is 2.60, which is 14.2% below the current share price.
  • The average PHASEBIO PHARMA stock price for the last 52 weeks is 3.58.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
PHASEBIO PHARMA Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 4.1494 5.7100 6.7900 2.6800 3.3600 -45.01%
2019 7.0928 3.1350 14.6600 2.7000 6.1100 97.73%
2018 3.9618 5.0000 5.3600 2.5600 3.0900 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.147B $0.000B
PhaseBio Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. The company's product consists of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor and PB1046, a once-weekly fusion protein for the treatment of pulmonary arterial hypertension, which are in clinical stage. PhaseBio Pharmaceuticals Inc. is based in Malvern, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71